Bolt Biotherapeutics Inc (BOLT) concluded trading on Wednesday at a closing price of $0.32, with 10.45 million shares of worth about $3.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.94% during that period and on May 21, 2025 the price saw a loss of about -3.85%. Currently the company’s common shares owned by public are about 38.34M shares, out of which, 25.23M shares are available for trading.
Stock saw a price change of -9.43% in past 5 days and over the past one month there was a price change of -12.19%. Year-to-date (YTD), BOLT shares are showing a performance of -40.76% which decreased to -60.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $0.81 during that period. The average intraday trading volume for Bolt Biotherapeutics Inc shares is 296.24K. The stock is currently trading -9.24% below its 20-day simple moving average (SMA20), while that difference is down -14.55% for SMA50 and it goes to -40.53% lower than SMA200.
Bolt Biotherapeutics Inc (NASDAQ: BOLT) currently have 38.34M outstanding shares and institutions hold larger chunk of about 19.09% of that.
The stock has a current market capitalization of $12.15M and its 3Y-monthly beta is at 0.93. It has posted earnings per share of -$1.66 in the same period. It has Quick Ratio of 3.13 while making debt-to-equity ratio of 0.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BOLT, volatility over the week remained 17.90% while standing at 10.65% over the month.
Stock’s fiscal year EPS is expected to rise by 24.73% while it is estimated to increase by 20.61% in next year. EPS is likely to grow at an annualized rate of 24.06% for next 5-years, compared to annual growth of -13.73% made by the stock over the past 5-years.
Coverage by SVB Leerink stated Bolt Biotherapeutics Inc (BOLT) stock as an Outperform in their note to investors on March 02, 2021, suggesting a price target of $36 for the stock. On March 02, 2021, Stifel Initiated their recommendations, while on March 02, 2021, Morgan Stanley Initiated their ratings for the stock with a price target of $45. Stock get a Buy rating from Guggenheim on March 02, 2021.
